

09-J1000-39

Original Effective Date: 10/01/11

Reviewed: 06/11/25

Revised: 07/15/25

Subject: Multiple Sclerosis Self Injectable Therapy (Interferon beta products and Copaxone)

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

Position Statement	Billing/Coding	Reimbursement	Program Exceptions	Definitions	Related Guidelines
Other	References	Updates			

DESCRIPTION:

Multiple sclerosis (MS) is a chronic disease affecting the central nervous system (CNS). It is characterized by triad of inflammation, demyelination, and scarring of the central nervous system and manifests as pathological (immune-mediated CNS demyelination and axonal injury) and clinical (exacerbations, disability progression) dissemination in time and space. Although the clinical course of the disease is capricious, MS has been categorized into four types: clinically isolated syndrome (CIS), relapsing-remitting (RRMS), secondary progressive (SPMS), and primary progressive (PPMS). The most common type is RRMS, which is characterized by acute attacks followed by periods of remission. An initial attack may present as a clinically isolated syndrome (CIS); individuals presenting with this syndrome are high risk for subsequent conversion to clinically definite MS (CDMS) when coupled with MRI lesions consistent with MS.

Although a cure for MS remains elusive, several treatment options slow the progression of the disease and reduce the frequency of relapses. These include dimethyl fumarate (Tecfidera), fingolimod (Gilenya), glatiramer acetate (Copaxone, Glatopa), interferon beta-1a (Avonex, Rebif), interferon beta-1b (Betaseron, Extavia), natalizumab (Tysabri), peg-interferon beta-1a (Plegridy), teriflunomide (Aubagio), alemtuzumab (Lemtrada), and ocrelizumab (Ocrevus).

The exact mechanism by which interferon (IFN) beta therapy exerts its beneficial effects is not clearly delineated; however, multiple clinical studies have demonstrated the ability of IFN beta preparations to reduce the number and severity of relapses and the number of new lesions appearing on magnetic resonance imaging (MRI). IFN beta preparations may also reduce the long-term progression of MS. To date, several head-to-head studies have evaluated differences in the beneficial effects (i.e., clinical, MRI measures of response) between the different types of IFN beta preparations; unfortunately, clinical

interpretation of the results is limited by methodologic problems (e.g., short duration, non-blinded design, non-standardized dosages and/or routes of administration). As such, no consensus has been reached as to whether one preparation should be used in favor over the other.

Glatiramer acetate is also considered a first line option for the treatment of individuals with RRMS. Although glatiramer acetate has not demonstrated efficacy in slowing, reversing, or halting the progression of the disease, it has been proven to delay the time to CDMS among patients who have experienced a first clinical episode and have MRI results consistent with MS. While the efficacy of glatiramer acetate relative to IFN beta therapy has not been established, it may be useful in members who do not respond adequately to or who do not tolerate IFN beta therapy.

POSITION STATEMENT:

Comparative Effectiveness

The Food and Drug Administration has deemed the drug(s) or biological product(s) in this coverage policy to be appropriate for self-administration or administration by a caregiver (i.e., not a healthcare professional). Therefore, coverage (i.e., administration) in a provider-administered setting such as an outpatient hospital, ambulatory surgical suite, physician office, or emergency facility is not considered medically necessary.

NOTE: Avonex, Betaseron, Kesimpta, Mavenclad, Mayzent, Plegridy, Rebif, and Zeposia are the preferred brand products for treatment of relapsing forms of multiple sclerosis. The preferred generic products include dimethyl fumarate (generic), fingolimod (generic), glatiramer acetate (generic by Mylan), and teriflunomide (generic). Dimethyl fumarate (generic), fingolimod (generic), glatiramer acetate (generic by Mylan and Glatopa), and teriflunomide (generic) do not require prior authorization.

Initiation of Avonex, Rebif, Plegridy or Betaseron **meets the definition of medical necessity** when **ALL** of the following criteria are met:

1. The member has a diagnosis of **ONE** of the following forms of multiple sclerosis (MS):
 - a. Relapsing-remitting MS [RRMS]
 - b. Active secondary-progressive MS [SPMS]
 - c. First clinical episode and the member has MRI features consistent with MS
2. The dosage does not exceed FDA approved labeling for the individual agents listed in Table 1.
3. Interferon therapy is **NOT** used in combination with **ANY** of the following:
 - a. Alemtuzumab (Lemtrada)
 - b. Cladribine (Mavenclad)
 - c. Dimethyl fumarate (Tecfidera)
 - d. Diroximel fumarate (Vumerity)
 - e. Fingolimod (Gilenya, Tascenso ODT)
 - f. Glatiramer acetate products (Copaxone, glatiramer acetate, Glatopa)

- g. Interferon beta-1a (Avonex, Rebif)
- h. Interferon beta-1b (Betaseron, Extavia)
- i. Mitoxantrone (Novantrone)
- j. Monomethyl fumarate (Bafiertam)
- k. Natalizumab (Tysabri)
- l. Ocrelizumab (Ocrevus)
- m. Ofatumumab (Kesimpta)
- n. Ozanimod (Zeposia)
- o. Peg-interferon beta-1a (Plegridy)
- p. Ponesimod (Ponvory)
- q. Rituximab (Rituxan or biosimilars)
- r. Siponimod (Mayzent)
- s. Teriflunomide (Aubagio)
- t. Ublituximab (Briumvi)

Approval duration: 1 year

Initiation of Extavia **meets the definition of medical necessity** when **ALL** of the following criteria are met:

1. The member has a diagnosis of **ONE** of the following forms of multiple sclerosis (MS)::
 - a. Relapsing-remitting MS [RRMS]
 - b. Active secondary-progressive MS [SPMS]
 - c. First clinical episode and the member has MRI features consistent with MS
2. **ONE** of the following (a,b,or c) – documentation must be submitted:
 - a. The patient has highly active MS disease activity and **BOTH** of the following:
 - i. The patient has ≥ 2 relapses in the previous year
 - ii. **ONE** of the following:
 1. The patient has ≥ 1 gadolinium enhancing lesion on MRI
 2. The patient has significant increase in T2 lesion load compared with a previous MRI
 - b. The patient has been treated with at least 3 MS agents from different drug classes
 - c. **BOTH** of the following (i and ii):
 - i. **ONE** of the following (1,2,or 3):

1. The patient has tried and had an inadequate response to dimethyl fumarate (generic), fingolimod (generic), glatiramer acetate (generic by Mylan, Glatopa), **OR** teriflunomide (generic)
 2. The patient has an intolerance (defined as an intolerance to the drug or its excipients, not to the route of administration) or hypersensitivity to dimethyl fumarate (generic), fingolimod (generic), glatiramer acetate (generic by Mylan, Glatopa), **OR** teriflunomide (generic)
 3. The patient has a FDA labeled contraindication to both dimethyl fumarate (generic), fingolimod (generic), glatiramer acetate (generic by Mylan, Glatopa), **AND** teriflunomide (generic)
- ii. **ONE** of the following (1,2,or 3):
1. The patient has tried and had an inadequate response to ONE preferred brand agent (Avonex, Betaseron, Kesimpta, Mavenclad, Mayzent, Plegridy, Rebif, Zeposia)
 2. The patient has an intolerance (defined as an intolerance to the drug or its excipients, not to the route of administration) or hypersensitivity to ONE preferred brand agent (Avonex, Betaseron, Kesimpta, Mavenclad, Mayzent, Plegridy, Rebif, Zeposia)
 3. The patient has a FDA labeled contraindication to ALL preferred brand agents (Avonex, Betaseron, Kesimpta, Mavenclad, Mayzent, Plegridy, Rebif, Zeposia)
3. The dosage does not exceed FDA approved labeling for the individual agents listed in Table 1.
 4. Interferon therapy is **NOT** used in combination with **ANY** of the following:
 - a. Alemtuzumab (Lemtrada)
 - b. Cladribine (Mavenclad)
 - c. Dimethyl fumarate (Tecfidera)
 - d. Diroximel fumarate (Vumerity)
 - e. Fingolimod (Gilenya, Tascenso ODT)
 - f. Glatiramer acetate products (Copaxone, glatiramer acetate, Glatopa)
 - g. Interferon beta-1a (Avonex, Rebif)
 - h. Interferon beta-1b (Betaseron, Extavia)
 - i. Mitoxantrone (Novantrone)
 - j. Monomethyl fumarate (Bafiertam)
 - k. Natalizumab (Tysabri)
 - l. Ocrelizumab (Ocrevus)
 - m. Ofatumumab (Kesimpta)
 - n. Ozanimod (Zeposia)

- o. Peg-interferon beta-1a (Plegridy)
- p. Ponesimod (Ponvory)
- q. Rituximab (Rituxan or biosimilars)
- r. Siponimod (Mayzent)
- s. Teriflunomide (Aubagio)
- t. Ublituximab (Briumvi)

Approval duration: 1 year

Initiation of brand Copaxone **meets the definition of medical necessity** when **ALL** of the following criteria are met

1. The member has a diagnosis of **ONE** of the following forms of multiple sclerosis (MS):
 - a. Relapsing-remitting MS [RRMS]
 - b. Active secondary-progressive MS [SPMS]
 - c. First clinical episode and the member has MRI features consistent with MS
2. The member has tried and had intolerable adverse effects to glatiramer acetate (by Mylan) and Glatopa and **ALL** of the following must be submitted:
 - a. The specific intolerance(s) and rationale for using brand Copaxone must be specified
 - b. Completed Medwatch reporting form (FDA 3500) - <https://www.fda.gov/safety/medical-product-safety-information/forms-reporting-fda>
 - c. Completed Naranjo Adverse Drug reaction probability scale - <https://www.floridablue.com/docview/Naranjo-assessment-PDF/>
3. **ONE** of the following (a,b,or c) – documentation must be submitted:
 - a. The patient has highly active MS disease activity and **BOTH** of the following:
 - i. The patient has ≥ 2 relapses in the previous year
 - ii. **ONE** of the following:
 1. The patient has ≥ 1 gadolinium enhancing lesion on MRI
 2. The patient has significant increase in T2 lesion load compared with a previous MRI
 - b. The patient has been treated with at least 3 MS agents from different drug classes
 - c. **ONE** of the following (i, ii, or iii):
 - i. The patient has tried and had an inadequate response to **ONE** preferred brand agent (Avonex, Betaseron, Kesimpta, Mavenclad, Mayzent, Plegridy, Rebif, Zeposia)
 - ii. The patient has an intolerance (defined as an intolerance to the drug or its excipients, not to the route of administration) or hypersensitivity to **ONE**

preferred brand agent (Avonex, Betaseron, Kesimpta, Mavenclad, Mayzent, Plegridy, Rebif, Zeposia)

- iii. The patient has a FDA labeled contraindication to ALL preferred brand agents (Avonex, Betaseron, Kesimpta, Mavenclad, Mayzent, Plegridy, Rebif, Zeposia)
- 4. The dosage does not exceed FDA-approved labeling listed in Table 1.
- 5. Brand Copaxone is **NOT** used in combination with ANY of the following
 - a. Alemtuzumab (Lemtrada)
 - b. Cladribine (Mavenclad)
 - c. Dimethyl fumarate (Tecfidera)
 - d. Diroximel fumarate (Vumerity)
 - e. Fingolimod (Gilenya, Tascenso ODT)
 - f. Glatiramer acetate products (Copaxone, glatiramer acetate, Glatopa)
 - g. Interferon beta-1a (Avonex, Rebif)
 - h. Interferon beta-1b (Betaseron, Extavia)
 - i. Mitoxantrone (Novantrone)
 - j. Monomethyl fumarate (Bafiertam)
 - k. Natalizumab (Tysabri)
 - l. Ocrelizumab (Ocrevus)
 - m. Ofatumumab (Kesimpta)
 - n. Ozanimod (Zeposia)
 - o. Peg-interferon beta-1a (Plegridy)
 - p. Ponesimod (Ponvory)
 - q. Rituximab (Rituxan or biosimilars)
 - r. Siponimod (Mayzent)
 - s. Teriflunomide (Aubagio)
 - t. Ublituximab (Briumvi)

Approval duration: 1 year

Continuation of interferon beta-1a (Avonex, Rebif), interferon beta-1b (Betaseron, Extavia), or peg-interferon beta-1a (Plegridy) **meets the definition of medical necessity** for the treatment of RRMS, active SPMS, or clinically isolated syndrome when **ALL** of the following criteria are met:

- 1. Member has demonstrated a beneficial response to the requested agent
- 2. Authorization/reauthorization for the requested agent has been previously approved by Florida Blue or another health plan in the past 2 years, **OR** the member previously met all indication-specific initiation criteria

3. The dose does not exceed FDA-approved labeling as outlined in Table 1
4. Use is **NOT** in combination with any of the following:
 - a. Alemtuzumab (Lemtrada)
 - b. Cladribine (Mavenclad)
 - c. Dimethyl fumarate (Tecfidera)
 - d. Diroximel fumarate (Vumerity)
 - e. Fingolimod (Gilenya, Tascenso ODT)
 - f. Glatiramer acetate products (Copaxone, glatiramer acetate, Glatopa)
 - g. Interferon beta-1a (Avonex, Rebif)
 - h. Interferon beta-1b (Betaseron, Extavia)
 - i. Mitoxantrone (Novantrone)
 - j. Monomethyl fumarate (Bafiertam)
 - k. Natalizumab (Tysabri)
 - l. Ocrelizumab (Ocrevus)
 - m. Ofatumumab (Kesimpta)
 - n. Ozanimod (Zeposia)
 - o. Peg-interferon beta-1a (Plegridy)
 - p. Ponesimod (Ponvory)
 - q. Rituximab (Rituxan or biosimilars)
 - r. Siponimod (Mayzent)
 - s. Teriflunomide (Aubagio)
 - t. Ublituximab (Briumvi)

Approval duration: 1 year

Continuation of brand Copaxone **meets the definition of medical necessity** for the treatment of RRMS, active SPMS, or clinically isolated syndrome when **ALL** of the following criteria are met:

1. The member has tried and had intolerable adverse effects to glatiramer acetate (by Mylan) and Glatopa and **ALL** of the following must be submitted:
 - a. The specific intolerance(s) and rationale for using brand Copaxone must be specified
 - b. Completed Medwatch reporting form (FDA 3500) - <https://www.fda.gov/safety/medical-product-safety-information/forms-reporting-fda>
 - c. Completed Naranjo Adverse Drug reaction probability scale - <https://www.floridablue.com/docview/Naranjo-assessment-PDF/>
2. Member has demonstrated a beneficial response to the requested agent

3. Authorization/reauthorization for the requested agent has been previously approved by Florida Blue or another health plan in the past 2 years, **OR** the member previously met all indication-specific initiation criteria
4. The dose does not exceed FDA-approved labeling as outlined in Table 1
5. Use is **NOT** in combination with any of the following:
 - a. Alemtuzumab (Lemtrada)
 - b. Cladribine (Mavenclad)
 - c. Dimethyl fumarate (Tecfidera)
 - d. Diroximel fumarate (Vumerity)
 - e. Fingolimod (Gilenya, Tascenso ODT)
 - f. Glatiramer acetate products (Copaxone, glatiramer acetate, Glatopa)
 - g. Interferon beta-1a (Avonex, Rebif)
 - h. Interferon beta-1b (Betaseron, Extavia)
 - i. Mitoxantrone (Novantrone)
 - j. Monomethyl fumarate (Bafiertam)
 - k. Natalizumab (Tysabri)
 - l. Ocrelizumab (Ocrevus)
 - m. Ofatumumab (Kesimpta)
 - n. Ozanimod (Zeposia)
 - o. Peg-interferon beta-1a (Plegridy)
 - p. Ponesimod (Ponvory)
 - q. Rituximab (Rituxan or biosimilars)
 - r. Siponimod (Mayzent)
 - s. Teriflunomide (Aubagio)
 - t. Ublituximab (Briumvi)

Approval duration: 1 year

Table 1: Maximum Dosage Limits†

Drug	Maximum Dose
Avonex (IFN beta-1a)	30 mcg IM weekly
Rebif (IFN beta-1a)	44 mcg SQ 3 times a week
Betaseron (IFN beta-1b)	0.3 mg SQ every other day
Extavia (IFN beta-1b)	0.3 mg SQ every other day
Plegridy (peg-interferon beta-1a)	125 mcg every 14 days
Copaxone 20 mg (glatiramer acetate)	20 mg SQ daily
Copaxone 40 mg (glatiramer acetate)	40 mg SQ 3 times a week

†Based on FDA-approved labeling
 IFN=Interferon; IM=Intramuscularly; SQ=Subcutaneously

DOSAGE/ADMINISTRATION:

THIS INFORMATION IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND SHOULD NOT BE USED AS A SOURCE FOR MAKING PRESCRIBING OR OTHER MEDICAL DETERMINATIONS. PROVIDERS SHOULD REFER TO THE MANUFACTURER'S FULL PRESCRIBING INFORMATION FOR DOSAGE GUIDELINES AND OTHER INFORMATION RELATED TO THIS MEDICATION BEFORE MAKING ANY CLINICAL DECISIONS REGARDING ITS USAGE.

Table 2: FDA-Approved Indications and Recommended Dosing

Drug	FDA-approved indication	Usual Dosage	Comments
Avonex (IFN beta-1a)	Relapsing forms of MS†	30 mcg IM once a week	If a dose is missed, it should be given as soon as possible; do not give 2 injections within 2 days of each other
Rebif (IFN beta-1a)	Relapsing forms of MS†	22 or 44 mcg SQ three times weekly	Each dose should be given at least 48 hours apart. Refer to the package insert for titration schedule.
Plegridy (pegIFN beta-1a)	Relapsing forms of MS†	125 mcg every 14 days	For SQ injection only
Betaseron (IFN beta-1b)	Relapsing forms of MS†	0.25 mg SQ every other day	Refer to the package insert for titration schedule.
Extavia (IFN beta-1b)	Relapsing forms of MS†	0.25 mg SQ every other day	
Copaxone (glatiramer acetate)	Relapsing forms of MS†	20 mg SQ daily or 40 mg SQ three times a week	For SQ injection only; allow solution to warm to room temperature.
†Includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. IFN=Interferon; IM=Intramuscularly; SQ=Subcutaneously			

Table 3: Recommended Dosage Adjustments†

Avonex (IFN beta-1a)	No dosage adjustments are recommended for either hepatic or renal impairment
Rebif (IFN beta-1a)	Leukopenia and abnormal liver function tests may require a reduction in dose (see “Precautions/Warnings”). No dosage adjustments are recommended for renal impairment.
Plegridy (PegIFN beta-1a)	Dose should be titrated: 63 mcg on day 1, 94 mcg on day 15, and 125 mcg on day 29.
Betaseron (IFN beta-1b)	No dosage adjustments are available for either hepatic or renal impairment. See warnings for hepatic injury and renal dysfunction.
Extavia (IFN beta-1b)	

Copaxone (glatiramer acetate)	
†Interferon beta and glatiramer pharmacokinetics have not been determined in patients with hepatic or renal impairment; IFN=Interferon	

Table 4: Drug Availability

Avonex (IFN beta-1a)	<ul style="list-style-type: none"> • 30 mcg/0.5 mL prefilled syringe • 30 mcg/0.5 mL auto-injector for injection
Rebif (IFN beta-1a)	<ul style="list-style-type: none"> • 22 mcg/0.5 mL prefilled syringe or auto-injector • 44 mcg/0.5 mL prefilled syringe or auto-injector • Titration pack (contains six 22 mcg/0.5 mL and six 8.8 mcg/0.2 mL prefilled syringes or auto-injector)
Plegridy (PegIFN beta-1a)	<ul style="list-style-type: none"> • 125 mcg/0.5 mL prefilled pen • 125 mcg/0.5 mL prefilled syringe • Starter pack: 63 mcg/0.5 mL prefilled pen, 0.94 mcg/0.5 mL prefilled pen, 125 mcg/0.5 mL prefilled pen • Starter pack: 63 mcg/0.5 mL prefilled syringe, 0.94 mcg/0.5 mL prefilled syringe, 125 mcg/0.5 mL prefilled syringe
Betaseron (IFN beta-1b)	0.3 mg powder for injection kit (contains a single-use vial and a prefilled single-use syringe containing 1.2 mL of diluent)
Extavia (IFN beta-1b)	0.3 mg powder for injection kit (contains a single-use vial and a prefilled single-use syringe containing 1.2 mL of diluent)
Copaxone (glatiramer acetate)	20 mg/mL or 40 mg/mL prefilled syringe
IFN=Interferon	

CONTRAINDICATIONS:

Interferon beta: contraindicated in persons with a history of hypersensitivity to interferon beta or albumin (human)

Glatiramer acetate: contraindicated in persons with a history of hypersensitivity to glatiramer acetate or mannitol

PRECAUTIONS/WARNINGS:

Interferon beta (Avonex, Rebif, Betaseron, Extavia, Plegridy):

Hepatic injury: monitor liver function tests. Consider discontinuation if hepatic injury occurs.

Depression, suicide, and psychotic disorders: Monitor and report any symptoms. Consider discontinuation if depression occurs. Use with caution in persons with depression.

Injection site necrosis: Typically, injection site necrosis occurs within the first 4 months of therapy; however, post-marketing reports of injection site necrosis occurring over 1 year after initiation of therapy have been received. Necrosis may occur at single or multiple injection sites. Injection sites should be rotated on a regular basis and do not administer into the affected area until fully healed.

Anaphylaxis: Rare but significant allergic reactions can occur following interferon beta therapy.

Autoimmune disorders: There have been post-marketing reports of autoimmune disorders of multiple target organs, including idiopathic thrombocytopenia and hyper- and hypothyroidism. Rare cases of autoimmune hepatitis have also been reported. Monitor patients for signs of these disorders and consider discontinuation.

Seizures: Use with caution in patients with preexisting seizure disorders. A relationship between occurrence of seizures and the use of Avonex® has not been established.

Decreased peripheral blood counts: monitor complete blood counts.

Thrombotic microangiopathy (TMA): cases have been reported. Discontinue if TMA occurs.

Pulmonary Arterial Hypertension: cases of pulmonary arterial hypertension (PAH) have been reported in patients treated with interferon beta products.

Congestive heart failure: monitor with preexisting cardiac disease or worsening cardiac symptoms.

Children: The safety and efficacy of glatiramer have not been established in persons younger than 18 years of age.

Pregnancy and Nursing:

- There are no adequate and well-controlled studies of interferon beta preparations in pregnant women.
- Additionally, no human studies have investigated the effects of interferon beta in breast-fed infants. According to the manufacturers of Betaseron and Extavia, these agents should be avoided in breast feeding. The manufacturers of Avonex and Rebif recommend cautious use of either product in nursing women.

Glatiramer acetate products (Copaxone)

Life-threatening and fatal anaphylaxis: Anaphylaxis can occur at any time following initiation from the first dose up to years after initial treatment. Most cases occurred within an hour after the injection. Signs may overlap with immediate post-injection reactions.

Immediate post-injection reaction: a constellation of symptoms immediately after injection that includes at least 2 of the following: anxiety, chest pain, constriction of the throat, dyspnea, flushing, palpitations, and urticaria. In general, it is typically transient and self-limiting and occurs after the first few months of treatment. This reaction may occur more than once in a given member.

Chest pain: Transient chest pain - without any long-term effects - may occur one or more times, either as part of the post-injection reaction or separately. While some of these episodes occurred in the context of the immediate post-injection reaction previously described, many did not.

Lipoatrophy and skin necrosis: Localized lipoatrophy and, rarely, injection site skin necrosis at injection sites have been reported during post-marketing experience. Careful rotation of injection sites is recommended so no single area is used for injections more than one time per week.

Effect on Immune response: Because glatiramer can modify immune response, it may interfere with immune functions. For example, treatment with glatiramer may interfere with the recognition of foreign antigens in a way that would undermine the body's tumor surveillance and its defenses against infection. Glatiramer acetate-reactive antibodies are formed in most patients receiving glatiramer acetate.

Hepatic Injury: cases of hepatic injury, some severe, including liver failure and hepatitis have been reported. This has occurred from days to years after initiating treatment. If signs or symptoms occur, consider discontinuation.

Injection errors: using an optional autoinjector that is not compatible may increase the risk for medication errors, such as dose omission or administration of a partial dose.

Children: The safety and efficacy of glatiramer have not been established in patients younger than 18 years of age.

Pregnancy and Nursing:

- There are no adequate and well-controlled studies of glatiramer acetate in pregnant women; however, administration of glatiramer acetate to pregnant rats and rabbits resulted in no adverse effects on fetal development at doses up to 37.5 mg/kg/day (18 and 36 times, respectively, the therapeutic human dose of 20 mg/day on a mg/m² basis).
- No human studies have investigated the effects of glatiramer acetate on breast-fed infants and caution in nursing women is recommended.

BILLING/CODING INFORMATION:

HCPCS Coding:

C9399	Unclassified drugs or biologicals (Plegridy)
J1595	Injection, glatiramer acetate, 20 mg (Copaxone)
J1826	Injection, interferon beta-1a, 30 mcg (Avonex)
J1830	Injection, interferon beta-1b, 0.25 mg (Betaseron, Extavia)
J3590	Unclassified biologic (Plegridy)
Q3027	Injection, interferon beta-1a, 1 mcg for subcutaneous use (Avonex)
Q3028	Injection, interferon beta-1a, 1 mcg for subcutaneous use (Rebif)

ICD-10 Diagnosis Codes That Support Medical Necessity:

G35	Multiple sclerosis
-----	--------------------

REIMBURSEMENT INFORMATION:

Refer to section entitled [POSITION STATEMENT](#).

PROGRAM EXCEPTIONS:

Federal Employee Program (FEP): Follow FEP guidelines.

State Account Organization (SAO): Follow SAO guidelines.

Medicare Advantage Products: No National Coverage Determination (NCD) and/or Local Coverage Determination (LCD) were found at the time of the last guideline revised date.

If this Medical Coverage Guideline contains a step therapy requirement, in compliance with Florida law 627.42393, members or providers may request a step therapy protocol exemption to this requirement if based on medical necessity. The process for requesting a protocol exemption can be found at [Coverage Protocol Exemption Request](#)

DEFINITIONS:

Clinically isolated syndrome (CIS): the first clinical presentation of disease that shows characteristics of inflammatory demyelination that could be MS but has yet to fulfill criteria of dissemination in time.

Primary-progressive multiple sclerosis (PPMS): Steadily progressive course from onset; occurs in 10-15% of patients with MS.

Relapsing-remitting multiple sclerosis (RRMS): Characterized by acute attacks followed by periods of remission; primary form of MS that occurs in approximately 85% of patients.

Secondary-progressive multiple sclerosis (SPMS): An initial period of RRMS, followed by a steadily progressive course, with acute relapses (active disease) or without acute relapses (not active disease); 75-85% of patients diagnosed with RRMS will transition to SPMS.

RELATED GUIDELINES:

[Alemtuzumab \(Lemtrada\), 09-J2000-27](#)

[Cladribine \(Mavenclad\), 09-J3000-34](#)

[Dimethyl Fumarate \(Tecfidera\), Diroximel fumarate \(Vumerity\), and Monomethyl fumarate \(Bafiertam\), 09-J1000-96](#)

[Fingolimod \(Gilenya\), 09-J1000-30](#)

[Natalizumab \(Tysabri\) IV, 09-J0000-73](#)

[Ocrelizumab \(Ocrevus\), 09-J2000-78](#)

[Ofatumumab \(Kesimpta\), 09-J3000-84](#)

[Ozanimod \(Zeposia\), 09-J3000-70](#)

[Siponimod \(Mayzent\), 09-J3000-35](#)

[Teriflunomide \(Aubagio\), 09-J1000-82](#)

OTHER:

None

REFERENCES:

1. AHFS Drug Information. Bethesda (MD): American Society of Health-System Pharmacists, Inc; 2016 [cited 2016-09-24].
2. Bayer. Betaseron (interferon beta-1b) injection. 2025 [cited 2025-05-28] In: DailyMed [Internet]. Bethesda (MD): National Library of Medicine. Available from: <http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66311f74-0472-4fa3-848a-06002ca0def5/>.
3. Biogen. Avonex (interferon beta-1a) injection. 2025 [cited 2025-05-28]. In: DailyMed [Internet]. Bethesda (MD): National Library of Medicine. Available from: <http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84d42ba4-6eef-41a7-a1d1-2cc887ef118d/>.
4. Biogen. Plegridy (peginterferon beta-1a) injection. 2025 [cited 2025-05-28]. In: DailyMed [Internet]. Bethesda (MD): National Library of Medicine. Available from: <http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08f0ea03-4e6d-195d-aef4-886e32bafa95/>.
5. Clinical Pharmacology [Internet]. Tampa (FL): Gold Standard, Inc.; 2025 [cited 2025-05-28]. Available from: <http://www.clinicalpharmacology.com/>.
6. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine; 2000 Feb 29 - [cited 2015-08-25]. Available from: <http://clinicaltrials.gov/>.
7. DRUGDEX® System [Internet]. Greenwood Village (CO): Thomson Micromedex; Updated periodically 2025 [cited 2025-05-28].
8. EMD Serono. Rebif (interferon beta-1a) injection. 2025 [cited 2025-05-28] In: DailyMed [Internet]. Bethesda (MD): National Library of Medicine. Available from: <http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6fcb5d2-8fcd-44fa-a838-b84ee5f44f0f/>.
9. Freedman MS. Treatment options for patients with multiple sclerosis who have suboptimal response to interferon- β therapy. *Eur J Neurol* 2014;21:377-87.
10. Gold R, Giovannoni G, Selmaj K et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomized, double-blind, placebo-controlled trial. *Lancet* 2013; 381: 2167-75.
11. Kappos L, Wiendl H, Selmaj K et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. *N Engl J Med*. 2015; 373: 1418-28.
12. Limmroth V. Treatment of relapsing-remitting multiple sclerosis: current and future algorithms. *Eur J Neurol* 2014;72:35-8.
13. Lublin FD, Reingold, SC, Cohen JA et al. Defining the clinical course of multiple sclerosis. *Neurology*. 2014; 83: 278-286.
14. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs. Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicenter, randomized, parallel, open-label trial. *Lancet Neurol* 2008;7:903-14.
15. Multiple Sclerosis Coalition. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence. Available at http://www.nationalmssociety.org/getmedia/5ca284d3-fc7c-4ba5-b005-ab537d495c3c/DMT_Consensus_MS_Coalition_color. Accessed 09/26/2016.
16. National Clinical Advisory Board of the National Multiple Sclerosis Society. Disease management consensus statement. Available at <http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/treatments/index.aspx> Accessed 08/13/2012.
17. National Multiple Sclerosis Society. Available at <http://www.nationalmssociety.org> Accessed 10/02/19.
18. Novartis. Extavia (interferon beta-1b) injection. 2025 [cited 2025-05-28] In: DailyMed [Internet]. Bethesda (MD): National Library of Medicine. Available from: <http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4cfdb571-ec4c-478f-bedc-e0669eeea504/>.

19. Oliver BJ, Kohli E, Kasper LH. Interferon therapy in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis of the comparative trials. J Neurol Sci 2011;302:96-105.
20. Orphan Drug Designations and Approval [Internet]. Silver Spring (MD): US Food and Drug Administration; 2025 [cited 2025-5-28]. Available from: <http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm/>.
21. Rae-Grant A, Day GS, Marrie RA et al. Practice guideline: Disease-modifying therapies for adults with multiple sclerosis: Report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. April 2018. Available at: <https://www.aan.com/Guidelines/home/GuidelineDetail/898>
22. Sandoz. Glatopa (glatiramer acetate) injection. 2025 [cited 2025-05-28] In: DailyMed [Internet]. Bethesda (MD): National Library of Medicine. Available from: <http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f01e40a-b6f6-40fb-b37c-3d06f1428e86/>.
23. Teva. Copaxone (glatiramer acetate) injection. 2025 [cited 2025-5-28] In: DailyMed [Internet]. Bethesda (MD): National Library of Medicine. Available from: <http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa88f583-4f5f-433b-80b4-1f4c9fb28357/>.
24. Wiendl H, Toyka KV, Rieckmann R, et.al. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 2008;255:1449-63.
25. Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc 2014;89:225-40.

COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Pharmacy Policy Committee on 06/11/25..

GUIDELINE UPDATE INFORMATION:

10/15/11	New Pharmacy Coverage Guideline.
10/15/12	Review and revision to guideline; consisting of revising description and position statement, updating dosage/administration, precautions/warnings, billing codes, definition, and references, and added contraindication section.
01/15/13	Revision to guideline; consisting of modifying position statement to disallow concurrent use of other MS agents.
04/15/13	Review and revision to guideline; consisting of revising position statement to include continuation criteria.
10/15/13	Review and revision to guideline; consisting of revising position statement to include orphan drug indications and approval duration; updating references and related guidelines.
01/01/14	Revision to guideline; consisting of updating position statement
03/15/14	Revision to guideline; consisting of updating position statement and other sections with newly approved dosing for glatiramer.
10/15/14	Review and revision to guideline; consisting of updating references.
01/01/15	Revision to guideline; consisting of updating position statement.
04/15/15	Revision to guideline; consisting of updating quantity limits for betaseron and extavia.
10/15/15	Review and revision to guideline; consisting of updating position statement, dosage/administration, coding, references.

11/01/15	Revision: ICD-9 Codes deleted.
01/01/17	Review and revision to guideline; consisting of updating position statement, dosage/administration, precautions, coding, and references.
10/15/17	Review and revision to guideline; consisting of updating position statement and references.
05/15/18	Revision to guideline; consisting of removal of daclizumab (product no longer available).
12/15/18	Review and revision to guideline; consisting of updating position statement and references.
04/01/19	Review and revision to guideline; consisting of updating position statement and references.
07/15/19	Review and revision to guideline; consisting of updating position statement and references.
11/15/19	Review and revision to guideline; consisting of updating position statement, description and references.
07/01/20	Revision to guideline; consisting of updating position statement.
10/01/20	Revision to guideline; consisting of updating the position statement.
04/01/20	Review and revision to guideline; consisting of updating the position statement.
05/15/22	Review and revision to guideline; consisting of updating the position statement to remove prior authorization from generic glatiramer acetate and updating the references.
01/01/23	Review and revision to guideline; consisting of updating the position statement to include generic fingolimod as a preferred generic and removal of Gilenya as a preferred brand. Updated documentation requirements of non-preferred brand agents.
05/15/23	Revision to guideline; consisting of updating the position statement to include generic teriflunomide as a preferred generic and removal of Aubagio as a preferred brand. Updated list of agents not to be used in combination.
10/01/23	Revision to guideline; consisting of removing Glatopa from the medical coverage guideline.
07/15/24	Review and revision to guideline; consisting of updating the position statement to remove step requirement.
07/15/25	Review and revision to guideline; consisting of updating the warnings and references.